Cephalon, Inc.

E.i. Dupont De Nemours and Company

Kyowa Hakko Kogyo Co., Ltd.

University of California

Kyowa Hakko Kogyo

James C Kauer

Michael E Lewis

Nicola T Neff

Mohamed A Iqbal

Chikara Murakata

Hiromitsu Saito

Yuzuru Matsuda

Marcie A Glicksman

Kathleen V Callison

Jill M Roberts-Lewis

Kevin R Smith

Sankar Chatterjee

James L Diebold

Robert Siman

Fumihiko Kanai

Masami Kaneko

Frank Baldino, Jr

William C Mobley

Frank M Longo

Frank Baldino

A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.

Treating disorders by application of insulin-like growth factors and analogs

Disclosed herein are inhibitors of the multicatalytic protease enzyme which are represented by the general formula: ##STR1## Constituent members and preferred constituent members are disclosed herein. Methodologies for making and using the disclosed compounds are also set forth herein.

Multicatalytic protease inhibitors

Treating disorders by application of insulin-like growth factors and

The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

Protein kinase inhibitors for treatment of neurological disorders

Protein kinase inhibitors for treatmen of neurological disorders

A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of at least one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.

A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method including the step of administering to the mammal one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.

K-252a derivatives for treatment of neurological disorders

Disclosed herein are inbibitors of the multicatalytic protease enzyme which are represented by the general formula: ##STR1## Constituent members and preferred constituent members are disclosed herein. Methodologies for making and using the disclosed compounds are also set forth herein.

The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. Also, a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

Selected protein kinase inhibitors for the treatment of neurological

The present invention provides both agonist and antagonist nerve growth factor peptides. The NGF blocking peptides can be used to inhibit the expression of mRNA and their encoded proteins whose expression is stimulated by NGF, such as .beta.-protein precursor and prion proteins, which proteins or their products are associated with neurodegenerative disorders, whereas the NGF agonist peptides can be used to treat neoplastic disorders such as neuroblastomas.

Nerve growth factor peptides

Method of enhancing the survival of neuronal cells, more preferably non-mitotic neuronal cells and/or cholinergic cells in a mammal, which cells are at risk of dying, which method includes administering to the mammal an effective amount of a functional derivative of Insulin-like Growth Factor I or Insulin-like Growth Factor II.

Growing community of inventors

Kennett Square, PA, United States of America

James C Kauer